School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
Drug Alcohol Rev. 2010 Jan;29(1):75-80. doi: 10.1111/j.1465-3362.2009.00100.x.
In 2003, a randomised controlled trial comparing injected diacetylmorphine and oral methadone was carried out in Andalusia, Spain. The subsequent follow-up study evaluated the health and drug use status of participants, 2 years after the completion of the trial.
This follow-up cohort study was carried out between March and August 2006. Data collected included information on socio-demographics, drug use, health and health-related quality of life. We compared data collected before randomisation and at 2 years for the following three groups: those currently on heroin-assisted treatment (C-HAT), those who have discontinued HAT (D-HAT), and those who have never received HAT (N-HAT).
From the total 62 randomised participants in 2003, 54 (87%) were interviewed for this study. Participants were distributed as follow: C-HAT 44.4% (24), N-HAT 22.2% (12) and D-HAT 33.3% (18). Illicit heroin use had a statistically significant decrease in the three groups from baseline to 2 years post trial. Mean days of heroin use were 2.42 (SD = 3.02); 6.56 (SD = 9.48) and 13.92 (SD = 12.59) for the C-HAT, D-HAT and N-HAT groups, respectively. Those currently on HAT were the only group that sustained at 2 years, their marked improvement in health after 9 months of treatment during the trial period.
Patients who received HAT showed better outcomes compared with those not on HAT. The results of this study strengthen the evidence showing that HAT can improve and stabilise the health of long-term heroin users with severe comorbidities and high mortality.
2003 年,在西班牙安达卢西亚进行了一项比较注射二乙酰吗啡和口服美沙酮的随机对照试验。随后的随访研究评估了参与者在试验完成后 2 年的健康和药物使用状况。
这是一项在 2006 年 3 月至 8 月进行的随访队列研究。收集的数据包括社会人口统计学、药物使用、健康和健康相关生活质量的信息。我们比较了以下三组在随机分组前和 2 年时收集的数据:正在接受海洛因辅助治疗的(C-HAT)、已停止海洛因辅助治疗的(D-HAT)和从未接受过海洛因辅助治疗的(N-HAT)。
在 2003 年的 62 名随机参与者中,有 54 名(87%)接受了这项研究的访谈。参与者的分布情况如下:C-HAT 44.4%(24 人)、N-HAT 22.2%(12 人)和 D-HAT 33.3%(18 人)。从基线到试验后 2 年,三组的非法海洛因使用均有显著下降。三组的平均海洛因使用天数分别为:C-HAT 组 2.42(SD=3.02);D-HAT 组 6.56(SD=9.48)和 N-HAT 组 13.92(SD=12.59)。目前正在接受 HAT 治疗的是唯一一组在 2 年内保持稳定的人群,他们在试验期间接受了 9 个月的治疗后,健康状况明显改善。
接受 HAT 的患者的治疗结果比未接受 HAT 的患者要好。这项研究的结果进一步证实了 HAT 可以改善和稳定长期使用海洛因、伴有严重合并症和高死亡率的患者的健康状况。